To september expect the u.s. medicinalselskab Gilead to produce enough of the drug Remdesivir to meet the global demand.
The report Gileads executive director, Daniel O'day, late Thursday night local time after a presentation of the company's quarterly results. It writes the news agency Reuters.
Remdesivir is the first drug in a major clinical study has shown effect on patients with covid-19, which is the disease caused by infection with the coronavirus.
this Medicine may decrease the indlæggelsestiden from 15 to 11 days, was the conclusion of the study, which is also performed in Denmark.
Gilead began this month on the commercial sale of the drug, which is given to inpatients coronapatienter.
In may, the UNITED states federal food and spa (FDA) permission for use of the product, but it is not yet fully approved, writes Reuters.
the Agent was in a very short time approved in the EU for the treatment of patients above 12 years of age with pneumonia and the need for treatment with oxygen.
so Far, the demand has on the Remdesivir surpassed the supply in many parts of the world, but it expects the managing director to change in the next few months.
Gilead arise in connection with the company's financial statements for the second quarter, it expects to produce two million or more Remdesivir treatments in 2020.
Gilead will also inform you that it now expects total sales in 2020 at between $ 23 billion and $ 25 billion.
It is something more than the previous expectations, which was between 21,8 billion and 22.2 billion dollars, writes Reuters.
on Wednesday, the EU Commission has an agreement with Gilead for the procurement of Remdesivir for 63 million euros. This corresponds to about 470 million kronor. It told the commission in a press release.